The experimental drug, which targets treatment of TTR-mediated amyloidosis, showed a 93% knockdown of circulating wild-type and mutant transthyretin, or TTR, genes. These mutant genes cause abnormal amyloid proteins to damage organs and tissue, resulting in progressive debilitation and ultimately leading to death. This good news led Piper Jaffray to raise its price target on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) from $36 to $42 per share. Even with this week’s nice bump, that target still represents another 11% upside. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s other piece of good news stemmed from pre-clinical data from its RNAi therapeutic program for the treatment of hemophilia and rare bleeding disorders. Experimental drug ALN-AT3 showed promise in treating hemophilia. The company plans to start a phase 1 study later this year.
Which of this week’s humongous stocks looks most likely to sustain an upward trajectory? Any or all of the three could keep advancing. I like Celldex Therapeutics, Inc. (NASDAQ:CLDX) and wouldn’t be surprised if it ultimately gains the interest of acquirers. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has solid potential as well. Perhaps the potential pop with the shortest fuse, though, is in Onyx. Look for a sale of the company in the near future for around $150 per share, if not more. That represents a 10% upside from current levels in what should be a relatively quick time frame. More fireworks could be in store soon.
The article 3 Humongous Health-Care Stocks This Week originally appeared on Fool.com is written by Keith Speights.
Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.
Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.